Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651741 | 0.88 | AR (0.50) | ARTAS2R14 | |
| SCHEMBL29880411 | 0.88 | AR (0.50) | ARTAS2R14 | |
| SCHEMBL16946784 | 0.88 | AR (0.52) | ARTAS2R14 | |
| SCHEMBL16823496 | 0.86 | TAS2R14 (0.53) | ARTAS2R14 | |
| SCHEMBL17176181 | 0.85 | L3MBTL1 (0.51) | AR | |
| SCHEMBL14289402 | 0.85 | AR (0.59) | AR | |
| SCHEMBL30901510 | 0.85 | AR (0.53) | ARTAS2R14 | |
| SCHEMBL21155661 | 0.85 | AR (0.55) | AR | |
| SCHEMBL21048280 | 0.85 | AR (0.53) | ARTAS2R14 | |
| SCHEMBL22492179 | 0.84 | AR (0.50) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-RE48461-E1 | Modulation of androgen receptor expression | lonis Pharmaceuticals, Inc. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190262315-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| US-9567588-B2 | Modulation of androgen receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9175291-B2 | Modulation of androgen receptor expression | ISIS PHARMACEUTICALS INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2015-04-23 | — | — | US | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885TAS2R14 4743/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | AR 2/4885TAS2R14 4346/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885TAS2R14 4743/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885TAS2R14 4346/4885 |
| US-20190262315-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885TAS2R14 4219/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | AR 2292/4885TAS2R14 4370/4885 |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885TAS2R14 4346/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885TAS2R14 4373/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885TAS2R14 4219/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885TAS2R14 4346/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885TAS2R14 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.